Federal Pharmaceutical: UBT48128 tablets have received clinical trial approval from the U.S. FDA.

Federal Pharmaceutical announced that its wholly-owned subsidiary, Federal Biotechnology Co., Ltd., has received approval from the U.S. Food and Drug Administration for the clinical trial registration application of its innovative Class 1 drug UBT48128 tablets, for indications related to overweight or obesity and type 2 diabetes.